Top

Published in:

01-03-2011 | Case Report

Severe osteoporosis treated with teriparatide in a patient affected by recessive epidermolysis bullosa dystrophica

Authors: L. Moretti, A. Notarnicola, A. Panella, L. Garofalo, R. Garofalo, A. Santamato, B. Moretti

Published in: Osteoporosis International | Issue 3/2011

Abstract

In this work, we describe the clinical and instrumental results of our experience, the first reported in the literature, of the administration of teriparatide to treat severe osteoporosis secondary to epidermolysis bullosa. Already after 2 months of therapy, the patient, a 20-year-old affected by a recessive form of epidermolysis bullosa dystrophica, had less pain and a functional recovery resulting in an improved autonomy; a satisfactory increase in the densitometric values was documented.

Lipozencić J (2009) News from the first regional symposium on hereditary epidermolysis bullosa, Mediterranean–central and eastern Europe. Acta Dermatovenerol Croat 17(2):147–148PubMed

Fewtrell MS, Allgrove J, Gordon I, Brain C, Atherton D, Harper J, Mellerio JE, Martinez AE (2006) Bone mineralization in children with epidermolysis bullosa. Br J Dermatol 154(5):959–962CrossRefPubMed

Mellerio JE, Weiner M, Denyer JE, Pillay EI, Lucky AW, Bruckner A, Palisson F (2007) Medical management of epidermolysis bullosa: proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. Int J Dermatol 46(8):795–800CrossRefPubMed

George M, Martinez AE, Mellerio JE, Nandi R (2009) Maxillary alveolar process fracture complicating intubation in a patient with epidermolysis bullosa. Paediatr Anaesth 19(7):706–707CrossRefPubMed

Schofield OM, Fine JD, Verrando P, Heagerty AH, Ortonne JP, Eady RA (1990) GB3 monoclonal antibody for the diagnosis of junctional epidermolysis bullosa: results of a multicenter study. J Am Acad Dermatol 23(6 Pt 1):1078–1083CrossRefPubMed

Mellerio JE, Denyer JE, Atherton DJ, Eady RA, McGrath JA (1990) Prognostic implications of determining 180 kDa bullous pemphigoid antigen (BPAG2) gene/protein pathology in neonatal junctional epidermolysis bullosa. Br J Dermatol 138(4):661–666CrossRef

Kawaguchi M, Mitsuhashi Y, Kondo S (1999) Osteoporosis in a patient with recessive dystrophic epidermolysis bullosa. Br J Dermatol 141(5):934–935CrossRefPubMed

Lin JT, Lane JM (2004) Osteoporosis: a review. Clin Orthop Relat Res 425:126–134CrossRefPubMed

Perman MJ, Lucky AW, Heubi JE, Azizkhan RG (2009) Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid. Arch Dermatol 145(1):95–96CrossRefPubMed

Title: Severe osteoporosis treated with teriparatide in a patient affected by recessive epidermolysis bullosa dystrophica
Authors: L. Moretti
A. Notarnicola
A. Panella
L. Garofalo
R. Garofalo
A. Santamato
B. Moretti
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 3/2011
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-010-1278-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Severe osteoporosis treated with teriparatide in a patient affected by recessive epidermolysis bullosa dystrophica

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Maternal vitamin D status affects bone growth in early childhood—a prospective cohort study

Development and validation of a disease model for postmenopausal osteoporosis

Effects of therapeutic exercise for persons with osteoporotic vertebral fractures: a systematic review

Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene

Proximal hip geometry and hip fracture risk assessment in a Korean population

Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment